Cancer Care · us
A New Option for ESR1-Mutated Advanced Breast Cancer: FDA Approves Giredestrant Combination Therapy
When disease progresses again after endocrine therapy, the next treatment choice often depends on tumor characteristics. The newly approved oral drug combination extended the time without disease progression in patients with ESR1 mutations, but whether it improves overall survival awaits further data.
For patients with advanced breast cancer that recurs or progresses after endocrine therapy, delaying the next disease progression is an important treatment goal. On November 16, the U.S. Food and Drug Administration (FDA) approved Genentech’s oral drug giredestrant in combination with everolimus, adding a treatment option for certain patients with ESR1 mutations. The trial supporting the approval showed that median progression-free survival in these patients increased from 5.5 months to 10 months.
The approval has a clearly defined scope: patients must be adults with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer and an ESR1 mutation confirmed by an FDA-authorized test. Their disease must also have recurred during or after adjuvant endocrine therapy, or progressed after at least one endocrine therapy regimen in the metastatic setting. The treatment is not applicable to all patients with breast cancer.
Giredestrant, marketed as Wilserdly, is an oral selective estrogen receptor degrader (SERD) that targets the estrogen receptor. Alongside the drug approval, the FDA also authorized FoundationOne Liquid CDx as a companion diagnostic to identify ESR1 mutations through circulating tumor DNA in the blood, making molecular testing a necessary step in selecting this therapy.
The approval was based on the randomized, open-label, multicenter phase 3 evERA trial, which enrolled 373 patients, including 207 with ESR1 mutations. Both groups received everolimus, combined with either giredestrant or a physician-selected endocrine drug such as exemestane, fulvestrant, or tamoxifen. Dana-Farber Cancer Institute stated that its Erica Mayer served as the trial’s principal investigator, that the study was funded by Roche, and that median follow-up was 18.6 months.
In the ESR1-mutated population, the hazard ratio for disease progression or death in the giredestrant group was 0.38, with a 95% confidence interval of 0.27 to 0.54. The objective response rate was 27%, compared with 14% in the control group. These results support improved disease control with the new combination, but 10 months is the median for the group and cannot be interpreted as a fixed duration of benefit for every patient.
Results in the overall trial population also need to be understood separately from those in the population covered by the approval. According to data released by Dana-Farber, the overall analysis, which included patients with and without ESR1 mutations, showed median progression-free survival of 8.8 months, compared with 5.5 months in the control group. This FDA approval remains limited to patients with ESR1 mutations. In addition, overall survival data were immature at the time of analysis. The benefit that can currently be established is delayed disease progression; there is not yet sufficient evidence to determine whether the treatment helps patients live longer.
Improved disease control also comes with a treatment burden. Common adverse reactions listed by the FDA and Targeted Oncology include stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, noninfectious pneumonitis, and nausea. The prescribing information also includes warnings for bradycardia and embryo-fetal toxicity. These safety data concern the combination therapy, and not all adverse reactions can be attributed to giredestrant alone.
Genentech said it expects to make the drug available in the United States within the coming weeks and to provide insurance assistance and a temporary drug bridging program. Between approval and actual treatment, patients still face hurdles involving mutation testing, access to the drug, and the burden of treatment. This development offers a new option selected on the basis of molecular characteristics, with evidence of disease control; its long-term survival benefit requires further follow-up.